Ironwood Pharmaceuticals
IRWD
142 hedge funds and large institutions have $2.14B invested in Ironwood Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 52 increasing their positions, 35 reducing their positions, and 11 closing their positions.
917% more call options, than puts
Call options by funds: $18.5M | Put options by funds: $1.82M
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
49% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 35
10% more funds holding
Funds holding: 129 → 142 (+13)
5% more capital invested
Capital invested by funds: $2.05B → $2.14B (+$92.1M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26M |
| 2 |
JP Morgan Chase
New York
|
+$17.1M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$14.8M |
| 4 |
BM
Bridger Management
New York
|
+$13.2M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$9.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$45.8M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$12M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.8M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$9.72M |
| 5 |
Morgan Stanley
New York
|
-$8.57M |
IRWD Hedge Fund Activity: Q1 2015 in Review
142 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2015, worth a combined $2.14B — up 4.5% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new IRWD positions and 11 closed out — a net gain of 14 holders — while 52 added to existing stakes and 35 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $26M. The largest seller was BVF Inc, cutting an estimated $45.8M.
- 142 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2015, up from 129 in Q4 2014.
- Funds reported $2.14B of Ironwood Pharmaceuticals stock for Q1 2015, up 4.5% quarter-over-quarter.
- 25 funds opened new Ironwood Pharmaceuticals positions in Q1 2015 and 11 closed out, a net change of +14 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2015 was T. Rowe Price Associates, an estimated $26M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2015 was BVF Inc, an estimated $45.8M sold.
Based on aggregated 13F filings for Q1 2015.